사나 바이오테크놀로지 (SANA)

Sana Biotechnology Inc 주식(SANA)의 최신 뉴스

Sana Biotechnology to Present at May and June 2024 Investor Conferences

GlobeNewswire Inc.

4 Stocks to Keep a Tab on for Amazing Earnings Acceleration

Zacks Investment Research

Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday

Benzinga

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

Benzinga

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

GlobeNewswire Inc.

Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference

GlobeNewswire Inc.

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

GlobeNewswire Inc.

Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire Inc.

PayPal Reports Q4 Results, Joins Rapid7, GoPro And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Benzinga

Sana Biotechnology Announces Pricing of Upsized Public Offering

GlobeNewswire Inc.

Sana Biotechnology Announces Proposed Public Offering of Common Stock

GlobeNewswire Inc.

Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice

Zacks Investment Research

Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why

Zacks Investment Research

Aspen Aerogels Issues Business Update, Joins Plug Power, SunPower And Other Big Stocks Moving Lower On Thursday

Benzinga

Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies

GlobeNewswire Inc.

Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc.

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

GlobeNewswire Inc.

Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System

GlobeNewswire Inc.

Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes

GlobeNewswire Inc.